Search

Your search keyword '"Irvine, Alan D."' showing total 1,270 results
Start Over Author "Irvine, Alan D."
1,270 results on '"Irvine, Alan D."'

2. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.

Author

Paller, Amy S, Flohr, Carsten, Eichenfield, Lawrence F, Irvine, Alan D, Weisman, Jamie, Soung, Jennifer, Pinto Correia, Ana, Natalie, Chitra R, Rodriguez Capriles, Claudia, Pierce, Evangeline, Reifeis, Sarah, Gontijo Lima, Renata, Armengol Tubau, Clara, Laquer, Vivian, and Weidinger, Stephan

Subjects
Adolescents, Efficacy, IL-13, Lebrikizumab, Moderate-to-severe atopic dermatitis, Safety, Depression, Mental Health, Clinical Research, Pediatric, Patient Safety, Clinical Trials and Supportive Activities, Brain Disorders, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Clinical Sciences
Abstract

IntroductionAtopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clinical benefit in previous Phase 3 trials: ADvocate1 (NCT04146363), ADvocate2 (NCT04178967), and ADhere (NCT04250337). We report 52-week safety and efficacy outcomes from ADore (NCT04250350), a Phase 3, open-label study of lebrikizumab in adolescent patients with moderate-to-severe AD. The primary endpoint was to describe the proportion of patients who discontinued from study treatment because of adverse events (AEs) through the last treatment visit.MethodsAdolescent patients (N = 206) (≥ 12 to

Published
2023

6. European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation

Author

Budu-Aggrey, Ashley, Kilanowski, Anna, Sobczyk, Maria K., Shringarpure, Suyash S., Mitchell, Ruth, Reis, Kadri, Reigo, Anu, Mägi, Reedik, Nelis, Mari, Tanaka, Nao, Brumpton, Ben M., Thomas, Laurent F., Sole-Navais, Pol, Flatley, Christopher, Espuela-Ortiz, Antonio, Herrera-Luis, Esther, Lominchar, Jesus V. T., Bork-Jensen, Jette, Marenholz, Ingo, Arnau-Soler, Aleix, Jeong, Ayoung, Fawcett, Katherine A., Baurecht, Hansjorg, Rodriguez, Elke, Alves, Alexessander Couto, Kumar, Ashish, Sleiman, Patrick M., Chang, Xiao, Medina-Gomez, Carolina, Hu, Chen, Xu, Cheng-jian, Qi, Cancan, El-Heis, Sarah, Titcombe, Philip, Antoun, Elie, Fadista, João, Wang, Carol A., Thiering, Elisabeth, Wu, Baojun, Kress, Sara, Kothalawala, Dilini M., Kadalayil, Latha, Duan, Jiasong, Zhang, Hongmei, Hadebe, Sabelo, Hoffmann, Thomas, Jorgenson, Eric, Choquet, Hélène, Risch, Neil, Njølstad, Pål, Andreassen, Ole A., Johansson, Stefan, Almqvist, Catarina, Gong, Tong, Ullemar, Vilhelmina, Karlsson, Robert, Magnusson, Patrik K. E., Szwajda, Agnieszka, Burchard, Esteban G., Thyssen, Jacob P., Hansen, Torben, Kårhus, Line L., Dantoft, Thomas M., Jeanrenaud, Alexander C.S.N., Ghauri, Ahla, Arnold, Andreas, Homuth, Georg, Lau, Susanne, Nöthen, Markus M., Hübner, Norbert, Imboden, Medea, Visconti, Alessia, Falchi, Mario, Bataille, Veronique, Hysi, Pirro, Ballardini, Natalia, Boomsma, Dorret I., Hottenga, Jouke J., Müller-Nurasyid, Martina, Ahluwalia, Tarunveer S., Stokholm, Jakob, Chawes, Bo, Schoos, Ann-Marie M., Esplugues, Ana, Bustamante, Mariona, Raby, Benjamin, Arshad, Syed, German, Chris, Esko, Tõnu, Milani, Lili A., Metspalu, Andres, Terao, Chikashi, Abuabara, Katrina, Løset, Mari, Hveem, Kristian, Jacobsson, Bo, Pino-Yanes, Maria, Strachan, David P., Grarup, Niels, Linneberg, Allan, Lee, Young-Ae, Probst-Hensch, Nicole, Weidinger, Stephan, Jarvelin, Marjo-Riitta, Melén, Erik, Hakonarson, Hakon, Irvine, Alan D., Jarvis, Deborah, Nijsten, Tamar, Duijts, Liesbeth, Vonk, Judith M., Koppelmann, Gerard H., Godfrey, Keith M., Barton, Sheila J., Feenstra, Bjarke, Pennell, Craig E., Sly, Peter D., Holt, Patrick G., Williams, L. Keoki, Bisgaard, Hans, Bønnelykke, Klaus, Curtin, John, Simpson, Angela, Murray, Clare, Schikowski, Tamara, Bunyavanich, Supinda, Weiss, Scott T., Holloway, John W., Min, Josine L., Brown, Sara J., Standl, Marie, and Paternoster, Lavinia

Published
2023
Full Text
View/download PDF

13. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types

Author

Bosma, Angela L., Ouwerkerk, Wouter, Heidema, Madeline J., Prieto-Merino, David, Ardern-Jones, Michael R., Beattie, Paula, Brown, Sara J., Ingram, John R., Irvine, Alan D., Ogg, Graham, Patel, Prakash, Reynolds, Nick J., Hearn, R.M. Ross, Wan, Mandy, Warren, Richard B., Woolf, Richard T., Hyseni, Ariënna M., Gerbens, Louise A.A., Spuls, Phyllis I., Flohr, Carsten, and Middelkamp-Hup, Maritza A.

Published
2023
Full Text
View/download PDF

16. The microbiome in patients with atopic dermatitis.

Author

Paller, Amy S, Kong, Heidi H, Seed, Patrick, Naik, Shruti, Scharschmidt, Tiffany C, Gallo, Richard L, Luger, Thomas, and Irvine, Alan D

Subjects
Skin, Humans, Staphylococcus aureus, Staphylococcal Skin Infections, Dermatitis, Atopic, Female, Male, Immunity, Innate, Adaptive Immunity, Microbiota, Atopic dermatitis, biotherapy, commensal, host-microbiome interaction, immune regulation, microbiome, Infectious Diseases, Genetics, Emerging Infectious Diseases, Clinical Research, Eczema / Atopic Dermatitis, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Immunology, Allergy
Abstract

As an interface with the environment, the skin is a complex ecosystem colonized by many microorganisms that coexist in an established balance. The cutaneous microbiome inhibits colonization with pathogens, such as Staphylococcus aureus, and is a crucial component for function of the epidermal barrier. Moreover, crosstalk between commensals and the immune system is now recognized because microorganisms can modulate both innate and adaptive immune responses. Host-commensal interactions also have an effect on the developing immune system in infants and, subsequently, the occurrence of diseases, such as asthma and atopic dermatitis (AD). Later in life, the cutaneous microbiome contributes to the development and course of skin disease. Accordingly, in patients with AD, a decrease in microbiome diversity correlates with disease severity and increased colonization with pathogenic bacteria, such as S aureus. Early clinical studies suggest that topical application of commensal organisms (eg, Staphylococcus hominis or Roseomonas mucosa) reduces AD severity, which supports an important role for commensals in decreasing S aureus colonization in patients with AD. Advancing knowledge of the cutaneous microbiome and its function in modulating the course of skin disorders, such as AD, might result in novel therapeutic strategies.

Published
2019

17. The VASCERN-VASCA working group diagnostic and management pathways for severe and/or rare infantile hemangiomas

Author

Diociaiuti, Andrea, Baselga, Eulalia, Boon, Laurence M., Dompmartin, Anne, Dvorakova, Veronika, El Hachem, May, Gasparella, Paolo, Haxhija, Emir, Ghaffarpour, Nader, Kyrklund, Kristiina, Irvine, Alan D., Kapp, Friedrich G., Rößler, Jochen, Salminen, Päivi, van den Bosch, Caroline, van der Vleuten, Carine, Kool, Leo Schultze, and Vikkula, Miikka

Published
2022
Full Text
View/download PDF

20. Lin−CD117+CD34+FcεRI+ progenitor cells are increased in chronic spontaneous urticaria and predict clinical responsiveness to anti‐IgE therapy.

Author

Ridge, Katie, Moran, Barry, Alvarado‐Vazquez, P. Abigail, Hallgren, Jenny, Little, Mark A., Irvine, Alan D., O'Farrelly, Cliona, Dunne, Jean, Finlay, Conor M., and Conlon, Niall

Subjects
BLOOD cells, PROGENITOR cells, MAST cells, RNA sequencing, BLOOD flow, URTICARIA
Abstract

Background: Chronic spontaneous urticaria (CSU) is a common, debilitating skin disorder characterized by recurring episodes of raised, itchy and sometimes painful wheals lasting longer than 6 weeks. CSU is mediated by mast cells which are absent from peripheral blood. However, lineage−CD34hiCD117int/hiFcεRI+ cells in blood have previously been shown to represent a mast cell precursor. Methods: We enumerated FcεRI−, FcεRI+ and FcεRIhi lineage−CD34+CD117+ cells using flow cytometry in blood of patients with CSU (n = 55), including 12 patients receiving omalizumab and 43 not receiving omalizumab (n = 43). Twenty‐two control samples were studied. Disease control and patient response to omalizumab was evaluated using the urticaria control test. We performed single‐cell RNA sequencing (scRNA‐Seq) on lineage−CD34hiCD117hi blood cells from a subset of patients with CSU (n = 8) and healthy controls (n = 4). Results: CSU patients had more lineage−CD34+CD117+FcεRI+ blood cells than controls. Lineage−CD34+CD117+FcεRI+ cells were significantly higher in patients with CSU who had an objective clinical response to omalizumab when compared to patients who had poor disease control 90 days after initiation of omalizumab. scRNA‐Seq revealed that lineage−CD34+CD117+FcεRI+ cells contained both lymphoid and myeloid progenitor lineages, with omalizumab responsive patients having proportionally more myeloid progenitors. The myeloid progenitor lineage contained small numbers of true mast cell precursors along with more immature FcεRI− and FcεRI+ myeloid progenitors. Conclusion: Increased blood CD34+CD117+FcεRI+ cells may reflect enhanced bone marrow egress in the setting of CSU. High expression of these cells strongly predicts better clinical responses to the anti‐IgE therapy, omalizumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Author

Hebert, Adelaide A., primary, Flohr, Carsten, additional, Hong, H. Chih-ho, additional, Irvine, Alan D., additional, Pierce, Evangeline, additional, Elmaraghy, Hany, additional, Pillai, Sreekumar, additional, Dawson, Zach, additional, Chen, Sherry, additional, Armengol, Clara, additional, Siegfried, Elaine, additional, and Weidinger, Stephan, additional

Published
2024
Full Text
View/download PDF

25. Distinct T cell signatures are associated with Staphylococcus aureus skin infection in pediatric atopic dermatitis

Author

Clowry, Julianne, primary, Dempsey, Daniel J., additional, Claxton, Tracey J., additional, Towell, Aisling M., additional, Turley, Mary B., additional, Sutton, Martin, additional, Geoghegan, Joan A., additional, Kezic, Sanja, additional, Jakasa, Ivone, additional, White, Arthur, additional, Irvine, Alan D., additional, and McLoughlin, Rachel M., additional

Published
2024
Full Text
View/download PDF

27. Dermatology COVID-19 Registries: Updates and Future Directions

Author

Freeman, Esther E., Chamberlin, Grace C., McMahon, Devon E., Hruza, George J., Wall, Dmitri, Meah, Nekma, Sinclair, Rodney, Balogh, Esther A., Feldman, Steven R., Lowes, Michelle A., Marzano, Angelo V., Naik, Haley B., Castelo-Soccio, Leslie, Lara-Corrales, Irene, Cordoro, Kelly M., Mahil, Satveer K., Griffiths, Christopher E.M., Smith, Catherine H., Irvine, Alan D., Spuls, Phyllis I., Flohr, Carsten, and French, Lars E.

Published
2021
Full Text
View/download PDF

29. The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata

Author

Meah, Nekma, Wall, Dmitri, York, Katherine, Bhoyrul, Bevin, Bokhari, Laita, Asz-Sigall, Daniel, Bergfeld, Wilma F., Betz, Regina C., Blume-Peytavi, Ulrike, Callender, Valerie, Chitreddy, Vijaya, Combalia, Andrea, Cotsarelis, George, Craiglow, Brittany, Donovan, Jeff, Eisman, Samantha, Farrant, Paul, Green, Jack, Grimalt, Ramon, Harries, Matthew, Hordinsky, Maria, Irvine, Alan D., Itami, Satoshi, Jolliffe, Victoria, King, Brett, Lee, Won-Soo, McMichael, Amy, Messenger, Andrew, Mirmirani, Paradi, Olsen, Elise, Orlow, Seth J., Piraccini, Bianca Maria, Rakowska, Adriana, Reygagne, Pascal, Roberts, Janet L., Rudnicka, Lidia, Shapiro, Jerry, Sharma, Pooja, Tosti, Antonella, Vogt, Annika, Wade, Martin, Yip, Leona, Zlotogorski, Abraham, and Sinclair, Rodney D.

Published
2021
Full Text
View/download PDF

30. Treat-to-target in dermatology:A scoping review and International Eczema Council survey on the approach in atopic dermatitis

Author

Renert-Yuval, Yael, Del Duca, Ester, Arents, Bernd, Bissonnette, Robert, Drucker, Aaron M., Flohr, Carsten, Guttman-Yassky, Emma, Hijnen, Dirkjan, Kabashima, Kenji, Leshem, Yael A., Paller, Amy S., Silverberg, Jonathan I., Simpson, Eric L., Spuls, Phyllis, Vestergaard, Christian, Wollenberg, Andreas, Irvine, Alan D., Thyssen, Jacob P., Renert-Yuval, Yael, Del Duca, Ester, Arents, Bernd, Bissonnette, Robert, Drucker, Aaron M., Flohr, Carsten, Guttman-Yassky, Emma, Hijnen, Dirkjan, Kabashima, Kenji, Leshem, Yael A., Paller, Amy S., Silverberg, Jonathan I., Simpson, Eric L., Spuls, Phyllis, Vestergaard, Christian, Wollenberg, Andreas, Irvine, Alan D., and Thyssen, Jacob P.

Abstract

Treat-to-target (T2T) is a pragmatic therapeutic strategy being gradually introduced into dermatology after adoption in several other clinical areas. Atopic dermatitis (AD), one of the most common inflammatory skin diseases, may also benefit from this structured and practical therapeutic approach. We aimed to evaluate existing data regarding the T2T approach in dermatology, with a specific focus on AD, as well as the views of International Eczema Council (IEC) members on the potential application of a T2T approach to AD management. To do so, we systematically searched for peer-reviewed publications on the T2T approach for any skin disease in the PubMed and Scopus databases up to February 2022 and conducted a survey among IEC members regarding various components to potentially include in a T2T approach in AD. We identified 21 relevant T2T-related reports in dermatology, of which 14 were related to psoriasis, five to AD, one for juvenile dermatomyositis and one for urticaria. In the IEC member survey, respondents proposed treatable traits (with itch, disease severity and sleep problems getting the highest scores), relevant comorbidities (with asthma being selected most commonly, followed by anxiety and depression in adults), recommended specialists that should define the approach in AD (dermatologists, allergists and primary care physicians were most commonly selected in adults), and applicable assessment tools (both physician- and patient-reported), in both adult and paediatric patients, for potential future utilization of the T2T approach in AD. In conclusion, while the T2T approach may become a useful tool to simplify therapeutic goals and AD management, its foundation in AD is only starting to build. A multidisciplinary approach, including a wide range of stakeholders, including patients, is needed to further define the essential components needed to utilize T2T in AD.

Published
2024

31. Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients.

Author

Brandling-Bennett, Heather A., Arkin, Lisa M., Chiu, Yvonne E., Hebert, Adelaide A., Callen, Jeffrey P., Castelo-Soccio, Leslie, Co, Dominic O., Cordoro, Kelly M., Curran, Megan L., Dalrymple, Austin M., Flohr, Carsten, Gordon, Ken B., Hanna, Diane, Irvine, Alan D., Kim, Susan, Kirkorian, A. Yasmine, Lara-Corrales, Irene, Lindstrom, Jill, Paller, Amy S., and Reyes, Melissa

Published
2024
Full Text
View/download PDF

32. Impact of climate change on atopic dermatitis: A review by the International Eczema Council.

Author

Wang, Sheng‐Pei, Stefanovic, Nicholas, Orfali, Raquel L., Aoki, Valeria, Brown, Sara J., Dhar, Sandipan, Eichenfield, Lawrence F., Flohr, Carsten, Ha, Alex, Mora, Camilo, Murase, Jenny E., Rosenbach, Misha, Srinivas, Sahana M., Thyssen, Jacob P., Wei, Maria L., Irvine, Alan D., and Abuabara, Katrina

Subjects
ATOPIC dermatitis, GREENHOUSE gases, CLIMATE change, ECZEMA, AIR pollution
Abstract

Atopic dermatitis (AD), the most burdensome skin condition worldwide, is influenced by climatic factors and air pollution; however, the impact of increasing climatic hazards on AD remains poorly characterized. Leveraging an existing framework for 10 climatic hazards related to greenhouse gas emissions, we identified 18 studies with evidence for an impact on AD through a systematic search. Most climatic hazards had evidence for aggravation of AD the impact ranged from direct effects like particulate matter‐induced AD exacerbations from wildfires to the potential for indirect effects like drought‐induced food insecurity and migration. We then created maps comparing the past, present, and future projected burden of climatic hazards to global AD prevalence data. Data are lacking, especially from those regions most likely to experience more climatic hazards. We highlight gaps important for future research: understanding the synergistic impacts of climatic hazards on AD, long‐term disease activity, the differential impact on vulnerable populations, and how basic mechanisms explain population‐level trends. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Filaggrin Expression and Processing Deficiencies Impair Corneocyte Surface Texture and Stiffness in Mice

Author

Thyssen, Jacob P., Jakasa, Ivone, Riethmüller, Christoph, Schön, Michael P., Braun, Andrea, Haftek, Marek, Fallon, Padraic G., Wróblewski, Jacek, Jakubowski, Hieronim, Eckhart, Leopold, Declercq, Wim, Koppes, Sjors, Engebretsen, Kristiane A., Bonefeld, Charlotte, Irvine, Alan D., Keita-Alassane, Sokhna, Simon, Michel, Kawasaki, Hiroshi, Kubo, Akiharu, Amagai, Masayuki, Matsui, Takeshi, and Kezic, Sanja

Published
2020
Full Text
View/download PDF

37. 502 - Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results

Author

Silverberg, Jonathan I, primary, Guttman-Yassky, Emma, additional, Simpson, Eric L, additional, Papp, Kim A, additional, Blauvelt, Andrew, additional, Chu, Chia-Yu, additional, Hong, H Chih-ho, additional, Stein Gold, Linda F, additional, Bieber, Thomas, additional, Kabashima, Kenji, additional, Rosmarin, David, additional, Gamelli, Amy, additional, Calimlim, Brian, additional, Vigna, Namita, additional, Hu, Xiaofei, additional, Yang, Yang, additional, Wu, Xiaoqiang, additional, Huang, Xiaohong, additional, Suravaram, Smitha, additional, Teixeira, Henrique D, additional, Raymundo, Eliza, additional, and Irvine, Alan D, additional

Published
2024
Full Text
View/download PDF

38. 509 - Dupilumab improves disease severity in children less than 12 years of age with moderate-severe AD: interim results from PEDISTAD real-world registry

Author

Baselga, Eulalia, primary, Ramien, Michele, additional, Marcoux, Danielle, additional, de Graaf, Marlies, additional, Irvine, Alan D, additional, Carvalho, Vania Oliveira, additional, Ardusso, Ledit R F, additional, Toledo-Bahena, Mirna, additional, Gupta, Rajan, additional, Tong, Thu, additional, and Zhang, Annie, additional

Published
2024
Full Text
View/download PDF

39. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure

Author

Bunick, Christopher, primary, Chovatiya, Raj, additional, Guttman, Emma, additional, Shahriari, Mona, additional, Boguniewicz, Mark, additional, Gao, Xinghua, additional, Greiwe, Justin, additional, Blauvelt, Andrew, additional, Schuttelaar, Marie L A, additional, Irvine, Alan D, additional, Levy, Gweneth F, additional, Platt, Andrew, additional, Dilley, Deanne, additional, Teixeira, Henrique, additional, Altman, Katherine, additional, Grada, Ayman, additional, and Silverberg, Jonathan, additional

Published
2024
Full Text
View/download PDF

43. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin

Author

McAleer, Maeve A, Pohler, Elizabeth, Smith, Frances JD, Wilson, Neil J, Cole, Christian, MacGowan, Stuart, Koetsier, Jennifer L, Godsel, Lisa M, Harmon, Robert M, Gruber, Robert, Crumrine, Debra, Elias, Peter M, McDermott, Michael, Butler, Karina, Broderick, Annemarie, Sarig, Ofer, Sprecher, Eli, Green, Kathleen J, McLean, WH Irwin, and Irvine, Alan D

Subjects
Human Genome, Pediatric, Genetics, Clinical Research, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Congenital, Skin, Child, Child, Preschool, DNA Mutational Analysis, Dermatitis, Desmoglein 1, Desmoplakins, Disease Progression, Humans, Hypersensitivity, Infant, Infant, Newborn, Male, Mutation, Missense, Pedigree, Protein Structure, Tertiary, Wasting Syndrome, Atopy, skin barrier, atopic dermatitis, desmosome, desmoplakin, atopic sensitization, eosinophilic esophagitis, Immunology, Allergy
Abstract

BackgroundSevere dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome is a recently recognized syndrome caused by mutations in the desmoglein 1 gene (DSG1). To date, only 3 families have been reported.ObjectiveWe studied a new case of SAM syndrome known to have no mutations in DSG1 to detail the clinical, histopathologic, immunofluorescent, and ultrastructural phenotype and to identify the underlying molecular mechanisms in this rare genodermatosis.MethodsHistopathologic, electron microscopy, and immunofluorescent studies were performed. Whole-exome sequencing data were interrogated for mutations in desmosomal and other skin structural genes, followed by Sanger sequencing of candidate genes in the patient and his parents.ResultsNo mutations were identified in DSG1; however, a novel de novo heterozygous missense c.1757A>C mutation in the desmoplakin gene (DSP) was identified in the patient, predicting the amino acid substitution p.His586Pro in the desmoplakin polypeptide.ConclusionsSAM syndrome can be caused by mutations in both DSG1 and DSP. Knowledge of this genetic heterogeneity is important for both analysis of patients and genetic counseling of families. This condition and these observations reinforce the importance of heritable skin barrier defects, in this case desmosomal proteins, in the pathogenesis of atopic disease.

Published
2015

44. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”

Author

Davidson, Wendy F., Leung, Donald Y.M., Beck, Lisa A., Berin, Cecilia M., Boguniewicz, Mark, Busse, William W., Chatila, Talal A., Geha, Raif S., Gern, James E., Guttman-Yassky, Emma, Irvine, Alan D., Kim, Brian S., Kong, Heidi H., Lack, Gideon, Nadeau, Kari C., Schwaninger, Julie, Simpson, Angela, Simpson, Eric L., Spergel, Jonathan M., Togias, Alkis, Wahn, Ulrich, Wood, Robert A., Woodfolk, Judith A., Ziegler, Steven F., and Plaut, Marshall

Published
2019
Full Text
View/download PDF

45. Clinical and genetic differences between pustular psoriasis subtypes

Author

Twelves, Sophie, Mostafa, Alshimaa, Dand, Nick, Burri, Elias, Farkas, Katalin, Wilson, Rosemary, Cooper, Hywel L., Irvine, Alan D., Oon, Hazel H., Kingo, Külli, Köks, Sulev, Mrowietz, Ulrich, Puig, Luis, Reynolds, Nick, Tan, Eugene Sern-Ting, Tanew, Adrian, Torz, Kaspar, Trattner, Hannes, Valentine, Mark, Wahie, Shyamal, Warren, Richard B., Wright, Andrew, Bata-Csörgő, Zsuzsa, Szell, Marta, Griffiths, Christopher E.M., Burden, A. David, Choon, Siew-Eng, Smith, Catherine H., Barker, Jonathan N., Navarini, Alexander A., and Capon, Francesca

Published
2019
Full Text
View/download PDF

47. Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

Author

Augustin, Matthias, primary, Nosbaum, Audrey, additional, Werfel, Thomas, additional, Grond, Susanne, additional, Reed, Catherine, additional, Lampropoulou, Anastasia, additional, Tietz, Nicole, additional, Irvine, Alan D., additional, and Riedl, Elisabeth, additional

Published
2023
Full Text
View/download PDF

48. Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study

Author

Eyerich, Kilian, primary, Gooderham, Melinda J., additional, Silvestre, Juan Francisco, additional, Shumack, Stephen P., additional, Mendes‐Bastos, Pedro, additional, Aoki, Valeria, additional, Ortoncelli, Michela, additional, Silverberg, Jonathan I., additional, Teixeira, Henrique D., additional, Chen, Shirley H., additional, Calimlim, Brian M., additional, Takemoto, Shunya, additional, Sancho, Cristina, additional, Fritz, Björn, additional, and Irvine, Alan D., additional

Published
2023
Full Text
View/download PDF

49. Treat‐to‐target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis

Author

Renert‐Yuval, Yael, primary, Del Duca, Ester, additional, Arents, Bernd, additional, Bissonnette, Robert, additional, Drucker, Aaron M., additional, Flohr, Carsten, additional, Guttman‐Yassky, Emma, additional, Hijnen, Dirkjan, additional, Kabashima, Kenji, additional, Leshem, Yael A., additional, Paller, Amy S., additional, Silverberg, Jonathan I., additional, Simpson, Eric L., additional, Spuls, Phyllis, additional, Vestergaard, Christian, additional, Wollenberg, Andreas, additional, Irvine, Alan D., additional, and Thyssen, Jacob P., additional

Published
2023
Full Text
View/download PDF

50. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial

Author

Flohr, Carsten, primary, Rosala-Hallas, Anna, additional, Jones, Ashley P, additional, Beattie, Paula, additional, Baron, Susannah, additional, Browne, Fiona, additional, Brown, Sara J, additional, Gach, Joanna E, additional, Greenblatt, Danielle, additional, Hearn, Ross, additional, Hilger, Eva, additional, Esdaile, Ben, additional, Cork, Michael J, additional, Howard, Emma, additional, Lovgren, Marie-Louise, additional, August, Suzannah, additional, Ashoor, Farhiya, additional, Williamson, Paula R, additional, McPherson, Tess, additional, O’Kane, Donal, additional, Ravenscroft, Jane, additional, Shaw, Lindsay, additional, Sinha, Manish D, additional, Spowart, Catherine, additional, Taams, Leonie S, additional, Thomas, Bjorn R, additional, Wan, Mandy, additional, Sach, Tracey H, additional, and Irvine, Alan D, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results